Literature DB >> 10519756

Cell cycle-associated proteins in melanotic neuroectodermal tumor of infancy.

P E de Souza1, F Merly, D M Maia, W H Castro, R S Gomez.   

Abstract

OBJECTIVE: The purpose of the present study was to compare the immunohistochemical expression of cell cycle-associated proteins in neuroblastic and melanocytic cell populations of melanotic neuroectodermal tumor of infancy. STUDY
DESIGN: Three cases of melanotic neuroectodermal tumor of infancy were selected. The immunohistochemical expression of MDM-2, p53, proliferating cell nuclear antigen, cyclin D1, and cyclin A was assessed through use of the streptavidin-biotin-peroxidase complex technique.
RESULTS: Positive immunostaining for MDM-2, proliferating cell nuclear antigen, cyclin D1, and cyclin A was occasionally observed in the large melanin-containing epithelioid cells.
CONCLUSIONS: These data suggest that MDM-2 expression may be important for the development of melanotic neuroectodermal tumor of infancy and that the melanocytic cell population, not the neuroblastic one, is the proliferative component of the tumor.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10519756     DOI: 10.1016/s1079-2104(99)70063-6

Source DB:  PubMed          Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod        ISSN: 1079-2104


  3 in total

1.  Melanotic Neuroectodermal Tumour of Infancy.

Authors:  B L Sapru; Priya Jeyaraj; B Mukherjee
Journal:  Med J Armed Forces India       Date:  2011-07-21

2.  Extensive Melanotic Neuroectodermal Tumor of Infancy.

Authors:  Assis Filipe Medeiros Albuquerque; José Ferreira Cunha; Rafael Linard Avelar; Eduardo Juca; Fabio Wildson Gurgel Costa; Mario Sérgio Macedo
Journal:  Head Neck Pathol       Date:  2015-11-18

3.  A germline mutation of CDKN2A and a novel RPLP1-C19MC fusion detected in a rare melanotic neuroectodermal tumor of infancy: a case report.

Authors:  David J Barnes; Edward Hookway; Nick Athanasou; Takeshi Kashima; Udo Oppermann; Simon Hughes; Daniel Swan; Dietrich Lueerssen; John Anson; A Bassim Hassan
Journal:  BMC Cancer       Date:  2016-08-12       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.